BioMérieux: Berenberg upgrades stock

(CercleFinance.com) - On Thursday, Berenberg upgraded bioMérieux shares from 'hold' to 'buy', with a target price raised from E99.
6 to E114.5, believing that the French microbiological diagnostics specialist is now firing on all cylinders.

While Berenberg believes that the lower-than-expected 2024 full-year forecasts communicated at the time of the 2023 earnings release do not come as a real surprise, the analyst points out that the excellent performance of the Spotfire multiplex PCR platform is far more surprising.

In this respect, Berenberg considers that the healthcare group's medium-term prospects are currently underestimated by the market, as the return to growth in respiratory testing is accompanied, in its opinion, by successful product launches and good performances in non-respiratory analysis.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.